OXY enters its Q1 2026 earnings today with the analyst community sharply split on valuation — yet the lending market is signalling almost no short-side conviction whatsoever.
The Street has been broadly lifting targets into the print. Wells Fargo moved the stock to Overweight in March and raised its target again in April, now at $72. Mizuho and UBS both pushed their targets higher last month. JPMorgan upgraded from Underweight to Neutral in March. Even the neutral camps have moved — Citigroup raised its target from $45 to $67. The message across most of these moves is the same: OXY was too cheap, but the upside story from here is more debated. Mean analyst target sits near $64, roughly 8% above the current price of $59.34. That's a modest implied upside — not a ringing endorsement, but not a crowded-short thesis either.
The borrow market confirms the lack of short conviction. Availability is extremely loose, with cost to borrow running at just 0.42% — near the bottom of its recent range and well below the brief spike to 7.7% seen in late March. That spike has fully reversed. Short interest is a modest 2.7% of the free float, up a small 2.3% on the day, but the one-week change is barely above flat. For context, availability stands far above the tight threshold that would signal meaningful squeeze pressure. Shorts are present but not building aggressively. Options positioning is also calm: the put/call ratio of 0.48 is barely above its 20-day average of 0.47, with a z-score near zero — almost no tilt toward defensive hedging into the report.
The bull case rests on two pillars: EPS momentum and earnings reliability. The company's 90-day EPS momentum ranks in the 97th percentile of the universe, and forward EPS estimates are growing year-over-year — a factor score in the 85th percentile. Consensus estimates for Q1 point to revenue near $5.7 billion and EPS of $0.59, with operating cash flow projected around $2.5 billion against capex of roughly $1.4 billion. Bears point to the $22 billion net debt load, an EV/EBIT rank in just the 24th percentile, and the analyst recommendation differential scoring in the 10th percentile — the spread between bullish and neutral/bearish ratings is unflattering. Berkshire Hathaway's 26.7% stake provides a structural floor for sentiment, but State Street added 3.1 million shares in Q1 and Dimensional Fund Advisors added 1.9 million, suggesting incremental institutional interest at lower prices earlier this year.
One wrinkle worth noting: peers across the E&P space outperformed OXY on both the day and the week. OVV gained over 10% on the week, APA added 9%, and CVE climbed 11.6% — all stronger moves than OXY's 1.2% weekly gain. Whether that reflects idiosyncratic concern about OXY's leverage or simply sector rotation, the underperformance relative to close peers is a live question heading into today's numbers.
The print will test whether OXY's cash generation profile — and management's progress on the $22 billion debt pile — can close the gap to a peer group that the market is currently rewarding more generously.
See the live data behind this article on ORTEX.
Open OXY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
